Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen

Abstract excerpt

Steps in the right direction HIV-1 mutates rapidly, making it difficult to design a vaccine that will protect people against all of the virus' iterations. A potential successful vaccine design might protect by eliciting broadly neutralizing antibodies (bNAbs), which target specific regions on HIV-1's trimeric envelope glycoprotein (Env) (see the Perspective by Mascola). Jardine et al. used mice engineered to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Herpesvirus Infections and Treatments
• Share to HIV Research and Treatment
• Share to Immune Cell Function and Interaction